Effects of dapagliflozin on body composition and liver tests in patients with non-alcoholic steatohepatitis associated with type 2 diabetes mellitus: A prospective, open-label, uncontrolled study

Conclusions Dapagliflozin was associated with improvements in body composition, most likely a reduction in visceral fat, which occurred together with improvements in liver tests and metabolic variables in patients with NASH associated with T2DM. Clinical trial registration: UMIN000023574
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research